Lupus

PR3+ in Lupus Nephritis https://t.co/rLdlAQYCfT https://t.co/CzLotVPwlh
Dr. John Cush @RheumNow( View Tweet )
Dec 01, 2023
Does GnRHa Reduce Premature Ovarian Insufficiency in SLE Patients on Cyclophosphamide? https://t.co/GVk2KLoGYq https://t.co/Hv9Bcn8cLg
Dr. John Cush @RheumNow( View Tweet )
Nov 29, 2023
The impact of SGLT2-inhibitor on SLE outcomes SLE is associated with increased risk of cardiovascular events due to both traditional and disease-specific risk factors. https://t.co/hyyMVQg3xV https://t.co/fLxh0vlTze
Dr. John Cush @RheumNow( View Tweet )
Nov 26, 2023
International study of 600 lupus pts - photosensitivity seen in 65% & was associated other lupus skin Dz (OR = 3.8). Fatigue was the most frequently reported systemic manifestation (82%). https://t.co/kjuvRZnB13 https://t.co/UTMNgiXbZZ
Dr. John Cush @RheumNow( View Tweet )
Nov 22, 2023
lupus_0.jpg

Early aggressive treatment in SLE: are we there yet?

Md Yuzaiful Md Yusof, MRCP(UK), PhD
Nov 21, 2023

Early treatment with DMARDs has revolutionised the outcomes of patients with rheumatic arthritis. However, this concept has not been fully extrapolated to other autoimmune rheumatic diseases such as systemic lupus erythematosus.

Read Article
Watch: Lupus Nephritis Therapy Paradigm Shift Dr. Yuz Yusof reporting on abstract 0782 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/m8SgtnVd95 https://t.co/cSexK2PCb5
Dr. John Cush @RheumNow( View Tweet )
Nov 20, 2023
Choices

JAKi and TYK2i: What to use and when?

Janet Pope, MD, MPH, FRCPC
Nov 20, 2023

You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. So, it is difficult to know which to choose.

Read Article
Lupus Topic Panel Featuring panelists Dr. Kathryn Dao, Eric Dein and Sheila Reyes, discussing the best and most interesting lupus studies presented at #ACR23. https://t.co/4lZmEBH8or https://t.co/L1ZTNeMFWr
Dr. John Cush @RheumNow( View Tweet )
Nov 19, 2023
Maintain Vigilance for CV Risk Postpartum in Autoimmune Diseases Pregnant women with ARDs and APS face significantly increased risks of CVEs. This increased risk is often attributed to ARDs, its medications or comorbidities associated with it. https://t.co/A2Keo8fH4p https://t.co/oHIYNNlzUU
Dr. John Cush @RheumNow( View Tweet )
Nov 18, 2023
Urinary biomarkers precede loss of kidney function for lupus nephritis In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation. https://t.co/MJb9F3uEgr https://t.co/oXvNLelE89
Dr. John Cush @RheumNow( View Tweet )
Nov 17, 2023
Less (Glucocorticoids) is More in Lupus Nephritis Dr. Yuz Yusof talks with Dr. Amir Saxena about abstract 0781 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/EriaJvBPj9 https://t.co/x5hNIAgBz2
Dr. John Cush @RheumNow( View Tweet )
Nov 17, 2023
Rheumatology,Roundup,2023

Rheumatology Roundup - ACR 2023

Jack Cush, MD
Nov 17, 2023

Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.

Read Article
ACR Best

#ACRbest Abstracts – Day 4

Jack Cush, MD
Nov 16, 2023

While there wasn’t much original new programming and research presented on the final day, that didn’t slow the RheumNow faculty from tweeting the noteworthy “Best of ACR” abstracts. Enjoy these below.

Read Article
lupus SLE

The impact of SGLT2-inhibitor on SLE outcomes

Md Yuzaiful Md Yusof, MRCP(UK), PhD
Nov 16, 2023

Since chronic kidney disease is one of the strongest CV risk factors, any new strategy to reduce proteinuria and avoid a decline in renal function may likely improve patient outcomes. In large cardiovascular outcome trials, the use of a fairly new-kid-on-the-block therapy, sodium–glucose

Read Article
#Yr in #Preview #ACR2023 J Buyon Pregnancies in #SLE have high #VTE risk - look at Ob/Gyn guidelines for prophylaxis of LMW #heparin - all SLE pregnancies recommend #ASA & #HCQ biomarkers for #renal #lupus, #HCQ levels ?aid #Rx -#SLE nephritis low prednisone 2 IS>1 @RheumNow

Janet Pope ( View Tweet )

Nov 16, 2023
#Hope for people with #SLE Insights from #ACR23 #Lupus #nephritis - half the oral #prednisone is = to 1 mg/kg induction after IV #solumedrol LESS PRED #Anifrolimumab reduces similarly skin, jts, other common organs in #SLE RCTS APPROX 2X improvement vs PBO @RheumNow @ACRheum https://t.co/OtdfTxZxr4
Janet Pope ( View Tweet )
Nov 16, 2023
Frail pts with SLE is associated with 🔸prolonged hospitalizations (28.89%), 🔸significantly higher in-pt mortality (2.88%) 🔸fewer days-to-readmission (59.8%) vs. non-frail pts with SLE (CLeung et al) Screen your SLE pts for frailty too. #ACR23 ABST2590 @RheumNow https://t.co/c4YP5h2ypn
sheila ( View Tweet )
Nov 16, 2023
female with hands

Are Rheumatologists doing Enough for Cervical Cancer?

Eric Dein, MD
Nov 15, 2023

Should rheumatologists be counseling patients on cervical cancer prevention and screening? The data from Abstract

Read Article
#ACR23 Abstr#2587 Can we agree on how to measure frailty in #SLE? A cohort study: moderate agreement at best among SLICC-FI, SPPB, FRAIL=>2 & PROMIS PF=<40. SLICC-FI was robust predictor of all outcomes except for cognitive impairment. FRAIL & PROMIS not far behind @RheumNow https://t.co/qWjM4crPvg
Md Yuzaiful Md Yusof ( View Tweet )
Nov 15, 2023
The Heart of Lupus During ACR 2023 Convergence, several abstracts were presented evaluating the prevalence of CV disease and exploring new tools to predict CV disease. The ones that caught my eye included... https://t.co/5Qk2fF3nlA #ACR23 https://t.co/Rja7K44BUf
Dr. John Cush @RheumNow( View Tweet )
Nov 15, 2023
COVAD2 data: ⬆️proportion of SLE pts from lmHDI countries were on CS(73% vs 59% p=0.0002), antimalarials(81% vs 68% p=0.0002) & IS(66% vs 53%p=0.0009) vs pts from hvhHDI countries Comorbids more in younger pts from lmHDI (prob from CS use) #ACR23 ABST2269 @RheumNow @rheumarhyme https://t.co/4CLGFYG1d0
sheila ( View Tweet )
Nov 15, 2023
L17 #ACR23 @RheumNow Afimetoran TLR7/8 inhib for cutaneous lupus Safety: No SAEs, mild-mod AEs, lower than PBO Nasopharyngitis & bronchitis Trough concentration consistent from D8 to 113, support 30 mg qd CLASI change; MCDI 50% Afim v 0% PB, CLASI-50 Afim 50% v 0% Inhib of IFNGS https://t.co/cKYY6rmIWE
Eric Dein ( View Tweet )
Nov 15, 2023
L17 @ #ACR23 New therapy on horizon for cutaneous LE (CLE)? ⭐️AFIMETORAN ➡️ TLR7/8 inhibitor ➡️1st-in-class orally bioavailable, potent ⭐️Phase Ib trial ➡️Criteria: 👉18-65 yo SLE vs biopsy proven CLE 👉CLE Dz Area & Severity Index (CLASI-A) at least 6 👉ANA… https://t.co/HPqw4d0AHl https://t.co/5u9aEvzdMb
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Nov 15, 2023
Telitacicept (BlyS/APRIL inhibitor) ph3 in RA wholly in China, after SLE approval there (SLE trial now w global sites) Efficacy okay, no better than other b/tsDMARDs What's the hook here, in a crowded RA market incl biosimilars? Safety does look good though #ACR23 L20 @RheumNow https://t.co/UzQ0f18E2A
David Liew @drdavidliew( View Tweet )
Nov 15, 2023
ICYMI Interesting study by Dr LWGarcia et al: 👉IFN-a serum levels predicted failure to respond to tx 2 years after a flare in pts w/ LN 👉Pts w/⬆️BL IFN-a levels had greater risk of having 2 or more subsequent flares #ACR23 ABST2297 @RheumNow @ZahiTouma https://t.co/WJZnNUPUbT
sheila ( View Tweet )
Nov 15, 2023

Recent Blogs

Focus on the Fasting Lipid Profile

Dr Paul Anthony John Russo
Sep 27, 2023
Blood labs
How best do we communicate CV risk associated with RA to other members of the treating team, most particularly the primary care physicians? After some experimentation, I have come up with an approach that seems to work and which does not take up much time. Read Post

A Brief History of Rheumatoid Arthritis Mimics

Robert Schoen, MD, MBA
Sep 06, 2023
books history
Imagine that 100 years from now, your great granddaughter, an eminent rheumatologist, reviews the history of rheumatoid arthritis mimics. Read Post

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2023 All Rights Reserved.

×